Showing 3491-3500 of 4164 results for "".
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrument
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- RETINA-AI Health Awarded US Patent for AI Detection of Eye Diseasehttps://modernod.com/news/retina-ai-health-awarded-us-patent-for-ai-detection-of-eye-disease/2479088/RETINA-AI Health has been awarded a US patent on its artificial intelligence (AI) systems for autonomous detection of eye diseases from images. There are several eye diseases such as diabetic retinopathy, macular degeneration, and glaucoma for which segments of the general population need to be r
- Zeiss Presents Integrated Workflow Advancements at AAOhttps://modernod.com/news/zeiss-presents-integrated-workflow-advancements-at-aao/2478534/The Medical Technology segment of Zeiss will present its latest integrated diagnostic and surgical advancements at the 2020 American Academy of Ophthalmology’s (AAO) Annual Meeting taking place virtually from Nov. 13-15. Zeiss will also be hosting multiple indu
- Scottish Medicines Consortium Accepts Iluvien for Prevention of Relapse in Recurrent Noninfectious Uveitishttps://modernod.com/news/scottish-medicines-consortium-accepts-iluvien-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis/2478259/The Scottish Medicines Consortium (SMC) has accepted Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS) in adults.1<
- Lenstec Submits Premarket Approval Application to FDA for SBL-3 IOLhttps://modernod.com/news/lenstec-submits-premarket-approval-application-to-fda-for-sbl3-iol/2477408/Lenstec has announced its has submitted a premarket approval (PMA) application to the FDA for the SBL-3 IOL. The Lenstec SBL-3 (segmented bifocal lens) is an asymmetric multifocal refractive IOL utilizing a 3-diopter add with a transition zone connecting the distanc
- EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-36-month-follow-up-data-for-second-phase-3-study-of-yutiq/2477336/EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second phase 3 trial of Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. “The d
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025https://modernod.com/news/expanding-product-needs-surgery-growth-will-drive-retinal-surgical-device-market-to-nearly-2-billion-by-2025/2477308/Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retinal surgical device market is expected to total more than $1.57 billion in 2020, with revenue rising
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the